Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 May 2019Website:
http://www.quincetx.comNext earnings report:
13 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:16:04 GMTDividend
Analysts recommendations
Institutional Ownership
QNCX Latest News
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3.
Two microcap biotech stocks to consider for the science-challenged among us.
What type of business is Quince Therapeutics?
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
What sector is Quince Therapeutics in?
Quince Therapeutics is in the Healthcare sector
What industry is Quince Therapeutics in?
Quince Therapeutics is in the Biotechnology industry
What country is Quince Therapeutics from?
Quince Therapeutics is headquartered in United States
When did Quince Therapeutics go public?
Quince Therapeutics initial public offering (IPO) was on 09 May 2019
What is Quince Therapeutics website?
https://www.quincetx.com
Is Quince Therapeutics in the S&P 500?
No, Quince Therapeutics is not included in the S&P 500 index
Is Quince Therapeutics in the NASDAQ 100?
No, Quince Therapeutics is not included in the NASDAQ 100 index
Is Quince Therapeutics in the Dow Jones?
No, Quince Therapeutics is not included in the Dow Jones index
When was Quince Therapeutics the previous earnings report?
No data
When does Quince Therapeutics earnings report?
The next expected earnings date for Quince Therapeutics is 13 May 2025